BEAM241220P29000
- 3.70
- 0.000.00%
Beam Therapeutics Newsroom
A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $42 to $80
Beam Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.
Beam Therapeutics Analyst Ratings
Promising Early Data and Innovative Approaches Lead to Buy Rating for Beam Therapeutics
J.P. Morgan Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $48
Analysts' Top Healthcare Picks: Stoke Therapeutics (STOK), Beam Therapeutics (BEAM)
William Blair Maintains Beam Therapeutics(BEAM.US) With Buy Rating
William Blair Remains a Buy on Beam Therapeutics (BEAM)
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80
Beam Therapeutics Is Maintained at Sector Perform by RBC Capital
Scotiabank Maintains Beam Therapeutics(BEAM.US) With Hold Rating, Cuts Target Price to $24
A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $31 to $69
Beam Therapeutics Analyst Ratings
JonesTrading Sticks to Their Hold Rating for Beam Therapeutics (BEAM)
Buy Rating Affirmed for Beam Therapeutics Due to Promising BEAM-101 Developments in Sickle Cell Disease Treatment
William Blair Maintains Beam Therapeutics(BEAM.US) With Buy Rating
Beam Therapeutics Price Target Announced at $24.00/Share by Scotiabank
Beam Therapeutics Analyst Ratings
Beam Therapeutics Initiated With a Sector Perform at Scotiabank
RBC Capital Maintains Beam Therapeutics(BEAM.US) With Hold Rating, Maintains Target Price $27